An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: Anti-inflammatory activity in Crohn's disease and experimental colitis in vivo

Gut

Volumn 53, Issue 3, 2004, Pages 339-345

  Stallmach, A ^a,b   Marth, T ^b   Weiss B ^b   Wittig, B M ^c   Hombach, A ^d   Schmidt, C ^b   Neurath, M ^e   Zeitz, M ^c   Zeuzem, S ^b   Abken, H ^d  

^a Clin Gastroenterol and Hepatol   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; GAMMA INTERFERON; GLUCOCORTICOID; HYBRID PROTEIN; IMMUNOGLOBULIN G2B; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; MESALAZINE; PROTEIN P40; PROTEIN SUBUNIT; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; ENTERITIS; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LAMINA PROPRIA; MALE; MONONUCLEAR CELL; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE; WEIGHT REDUCTION;

ADULT; ANIMALS; APOPTOSIS; CELL DIVISION; CELLS, CULTURED; COLITIS; CROHN DISEASE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN SUBUNITS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-12; RECOMBINANT FUSION PROTEINS; TRINITROBENZENESULFONIC ACID;

EID: 10744220844     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.020107     Document Type: Article

References (49)

1. Zeitz M. Pathogenesis of inflammatory bowel disease. Digestion 1997;58(suppl 1):59-61.
2. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998;115:182-205.
3. Breese E, Braegger CP, Corrigan G, et al. Interleukin-2-and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993;78:127-31.
4. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunology 1996;157:1261-70.
5. Parrello T, Montelleone G, Cucchiara S, et al. Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease. J Immunology 2000;165:7234-9.
6. Stallmach A, Marth T, Adrian T, et al. Increased expression of IL-12 receptor β2 mRNA in lamina propria mononucleor cells of patients with active Crohn's disease. Int J Colorectal Dis 2002;17:303-10.
7. Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin- 12-receptor system: Role in normal and pathologic immune responses. Annu Rev Immunol 1998;16:495-521.
8. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112:1169-78.
9. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997;150:823-32.
10. Berrebi D, Besnard M, Fromont-Hankard G, et al. Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. Am J Pathol 1998;152:667-72.
11. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
12. Ehrhardt RO, Ludviksson BR, Gray B, et al. Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol 1997;158:566-73.
13. Mattner F, Fischer S, Guckes S, et al. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol 1993;23:2202-8.
14. Ling PR, Gollaher C, Colon E, et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 1995;154:116-27.
15. Gillessen S, Corvajolm D, Ling P, et al. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol 1995;25:200-6.
16. Gately MK, Carvajal DM, Connoughton SE, et al. Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo. Ann N Y Acad Sci 1996;795:1-12.
17. Camoglio L, Juffermans NP, Peppelenbosch M, et al. Contrasting roles of IL-12p40 and IL-12p35 in the development of hapten-induced colitis. Eur J Immunol 2002;32:261-9.
18. + IFN-γ-producing cells. J Immunol 1997;158:643-8.
19. Magram J, Sfarra J, Connaughton S, et al. IL-12 deficient mice are defective but not devoid of type 1 cytokine responses. Ann N Y Acad Sci 1996;795:60-70.
20. Magram J, Connaughton S, Warrier R, et al. IL-12 deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunit 1996;4:471-81.
21. Stallmach A, Pfister K, Künne S, et al. Activation of β1 integrins mediates proliferation and inhibits apoptosis of intestinal CD4-positive lymphocytes. Eur J Immunol 2001;31:1228-38.
22. Lieschke GJ, Rao PK, Gately MK, et al. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 1997;15:35-40.
23. Seed B, Aruffo A. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci U S A 1987;84:3365-9.
24. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999;116:557-65.
25. Wittig B, Schwarzler C, Fohr N, et al. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J Immunol 1998;161:1069-73.
26. Stallmach A, Wittig BM, Giese T, et al. Protection of trinitrobenzene sulfonic acid-induced colitis by an interleukin-2-IgG2b fusion protein in mice. Gastroenterology 1999;117:866-76.
27. Barbulescu K, Becker C, Schlaak JF, et al. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J Immunol 1998;160:3642-7.
28. Kühn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
29. Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in seid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:553-62.
30. Groux H, O'Gara A, Bigler M. A CD4+ T cell subset inhibits antigen-specific T-cell response and prevents colitis. Nature 1997;389:737-41.
31. van Deventer SJH, Elson CO, Fedorak RN. Crohn's Disease Study Group. 1997. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997;113:383-9.
32. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000;119:1473-82.
33. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease. IL-10 Cooperative Study Group. Gastroenterology 2000;119:1461-72.
34. Colombel JF, Rutgeerts P, Malchow H, et al. 2001. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001;49:42-6.
35. Ina K, Itoh JK, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081.
36. Itoh J, De la Motte C, Strong SA, et al. 2001. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 2001;49:35-41.
37. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
38. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001;120:1330-8.
39. Rutgeerts P, D'Haens G, Targan S, et al. 1999. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody [infliximab] to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
40. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
41. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
42. Zhang Z, Correa H, Begue RE. Tuberculosis and treatment with infliximab. N Engl J Med 2002;346:623-6.
43. Holscher CAAR, Arendse B, Brown N, et al. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol 2001;167:6957-66.
44. Cooper AM, Kipnis A, Turner J, et al. Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular response to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol 2002;168:1322-7.
45. Elkins KL, Cooper A, Colombini SM, et al. 2002. In vivo clearance of an intracellular bacterium, Francisella tularensis LVS, is dependent on the p40 subunit of IL-12 but not only on IL12 p70. Infect Immun 2002;70:1936-48.
46. Ha SJ, Lee CH, Lee SB, et al. A novel function of IL-12p40 as a chemotactic molecule for macrophages. J Immunol 1999;163:2902-8.
47. Mullin GE, Galinkin D. Anti-IL12 imposes the death sentence on Th1 cells in TNBS colitis - is there a light at the end of the tunnel for Crohn's disease? Inflamm Bowel Dis 2000;6:261-2.
48. Strober W, Fuss I, Kitani A. Regulation of experimental mucosal inflammation. Acta Odontol Scand 2001;59:244-7.
49. Zheng XX, Steele AW, Nickerson PW, et al. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccaride-induced septic shock and allogenic islet transplantation. J Immunol 1995;154:5590-600.